"10.1371_journal.pone.0041358","none","2012-08-01T00:00:00Z","Takashi Kadowaki; Tetsuya Ohtani; Masato Odawara","Department of Diabetes and Metabolic Diseases, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan; sanofi-aventis K.K., Tokyo, Japan; Department of Diabetology, Metabolism, and Endocrinology, Tokyo Medical University, Tokyo, Japan","Conceived and designed the experiments: TO. Performed the experiments: TK MO. Analyzed the data: TO. Wrote the paper: TO. Contributed to final draft: TK MO.","The authors have read the journalâ€™s policy and have the following conflicts: Takashi Kadowaki received an honorarium for a lecture from sanofi-aventis K.K. Takashi Kadowaki and Masato Odawara received advisory board fees as publication committee members. Tetsuya Ohtani works for sanofi-aventis KK. Insulin glargine is marketed by Sanofi-Aventis under the name Lantus. There are no other patents, products in development or marketed products to declare. These do not alter The authors adherence to all the PLoS ONE policies on sharing data and materials.","2012","08","Takashi Kadowaki","TK",3,TRUE,1,2,1,1,TRUE,FALSE,FALSE,0,NA,FALSE
